PARSIPPANY, N.J., Aug.  07, 2026  (GLOBE NEWSWIRE) -- Embecta Corp. (&#34;embecta&#34;) (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies

EMBC

Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results

Embecta Reports Q3 FY2026 Results; Conference Call Today

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>PARSIPPANY, N.J., Aug.  07, 2026  (GLOBE NEWSWIRE) -- Embecta Corp. (&amp;#34;embecta&amp;#34;) (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Embecta disclosed its third-quarter fiscal 2026 results and will host a live 8:00 a.m. ET conference call and webcast for analysts and investors. The company reiterates its strategy to evolve from insulin delivery to a broad-based medical supplies player with about 2,000 employees globally. A detailed earnings press release and investor presentation are available on its IR site.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Embecta reports third-quarter FY2026 results; earnings press release issued.</li><li>Conference call scheduled for Aug 7, 2026 at 8:00 a.m. ET.</li><li>Embecta aims to become a broad-based medical supplies company; ~2,000 employees.</li><li>Investor presentation and webcast available on Embecta IR site.</li><li>Parsippany, New Jersey is the press release location.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Embecta Corp. (EMBC)</strong>: Primary company; earnings release and investor presentation; near-term price reaction tied to results and guidance.</li></ul>
  </section>

  <section data-block="category">
    <h3>Earnings</h3>
    <p>Category: Earnings. The article is an earnings release with an investor call and presentation, signaling a near-term focus on quarterly performance and strategic pivot toward broader medical supplies.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Earnings release and Q3 results may trigger intraday moves today.</li><li>Guidance or comments on expanding into broader medical supplies could impact valuation.</li><li>Investors will scrutinize the investor presentation for margin and product initiatives.</li><li>Absence of numbers in this release means initial read hinges on guidance.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Embecta Corp. (EMBC) reported third-quarter fiscal 2026 results.</li><li>Conference call scheduled for 8:00 a.m. ET on Aug 7, 2026.</li><li>Location listed: Parsippany, New Jersey.</li><li>Company employs approximately 2,000 people worldwide.</li><li>Strategic aim: become a broad-based medical supplies company.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term, EMBC may exhibit volatility around the earnings event; upside hinges on growth trajectory and pivot details.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>PARSIPPANY, N.J., Aug.  07, 2026  (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/EMBC">EMBC</a>), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported third quarter fiscal 2026 financial results.</p>  <p align="justify">Visit the company’s Investor Relations website at <a href="https://www.globenewswire.com/Tracker?data=YoX0UBC5uPVu-DULKDt3Zj9UbQe2bMb1dXobjOpdCT5Z1zKNYRKmMCbElHtvAtzdNvu2DU7gUig_gNPQJ6p10q3xQh6BPK-Zek7WJSc_6SGkqH6GByMKT148IJEhIHhf" rel="nofollow" target="_blank">http://investors.embecta.com</a> to view the detailed third quarter fiscal 2026 <a href="https://www.globenewswire.com/Tracker?data=3vfu00m3qVcLjap5o0fH34ve3rD6jk6w1oNDEjATjoZbGzSozLV5VS6Rry_0uZLKJSfuWfoIQMdxqlvsEr-5frvb0Ofcn3tMfOStR1ClHLIQBBcEyv4gIov2aNnEmJVB9axcUpgjiUORVotyVv4mfZ466IOtX20j8dBd83w6hr0=" rel="nofollow" target="_blank"><strong>earnings press release</strong></a> and investor presentation.</p>  <p align="justify">The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, Aug 7, 2026, which is accessible <a href="https://www.globenewswire.com/Tracker?data=KFRbfB-MFbe8hYEkeUWjk_FZmlgeCUpusbABZsuAlNopovHNeuLn95OIFeoAZ_-y9vK-6DhLqg_VnA2ozry757tkb1p9y4DgLduRFJQ7hAQ=" rel="nofollow" target="_blank">here</a>, or access the teleconference <a href="https://www.globenewswire.com/Tracker?data=KFRbfB-MFbe8hYEkeUWjk1ZNb_6ibusAx_nEXe5N872Z19oYtAfMtPkXNy0UPxC4sIka_GhAhxYzLbYS7-G3qlyVkCcZK7rHbkVb6ULfzIFswF4cgfISrRXzRQzvaKxH1OFc9McA108-LEnZI6wRsXWmOVi1V5b0VwLA0fj5za8=" rel="nofollow" target="_blank">here</a>. The live webcast can also be accessed via the company’s website at <a href="https://www.globenewswire.com/Tracker?data=j-4hfTHKv5Osve8nAixhXUa0apHtm6Bz4h-kDNx5VfGOPNDWboo45sgVSS05CJ2qfJU8iVPZZQXWslapyRPFYZvNOH8i53K3HpjCa_Oa4AE=" rel="nofollow" target="_blank">investors.embecta.com</a>.</p>  <p align="justify">A webcast replay of the call will be available beginning at 11:00 a.m. ET on Aug 7, 2026, via the embecta investor relations website and archived on the website for one year.</p>  <p><strong>About embecta </strong></p>  <p align="justify">embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=Y6DzlwCgkutH6utVLcYNDBRcrjsoVJtPqdy0Ey264YU7waJeTqLfeDBIhmxl4Q6x9Z0ZcmA8JU2NedMK1ME853GDgZMOch-cgyL0gj7ZcHtmRvh-j4R4l7sqUJO4-E-9olE8-U_SiRd2EBWIohnikgxv9KBZJLiH9saLFZc2gy2Tr4I9MrxKtQi9pqwHSK3iJWnKYymPfyxLpSxH_zmne3zpw1m5Wju_IfRjqydJI6MChr2ibmK-3fjGltN8y129KBiZx_aSQfD0UYBfJFTw8eSZF7cwdaG3-Wm9Ge7kpSM6VI38BTU4f3kw24_uUM72Qmay239V_b-0_Nrt3AGQr3KAKUm60--XlFTsAWmsbLckXPMTVAybbctBQKKdkbNdd3EvRSNE5CKydawJQROa1a2Eh3MNSRP7hkRijIT67Ihg-bHx6Bl6aozDCMDNbmzOiwjy-UYH8GgdBcBjRzp4IA5kmi73WdlzMFuldesTEIFRKmmz2f1tZ_83BrvjknY8ngZvhV51TWYrlHBJqBaKzxE8LXaiksWakdU3qzDrezOrPk8p4FMNQhOw0mmGbz2-dv9Q3KHGq352SukO-_3NbTRyZRqNOi_ANbn4rB2hON3ULS0u6ge9AQhVS1L0DRTsXq7wELl3S26s-xO5zH671r3RzfrdZtUBn-16W3i9TyOVCRDHFgmISedV99NlodRWO7EP5FK5TYzjp9-I3Au9iETVOMSItMViC80svd7mxUs=" rel="nofollow" target="_blank">embecta.com</a> or follow our social channels on <a href="https://www.globenewswire.com/Tracker?data=y6dU3l1YzhiO5Fd6HlZTZ-ZLPhWJILH6F0ECFwJfvU_O_QdsLC-ifpZSh6KR5uVBYf40k6N8l0_VxHwYtKZSAbNbaHNzsLHwJR0dnOrqpUgtAvNpSfh5hdENU5RfYERRx80-d80y6ISI25BamUSQAvJFFELeIvI6C6JUUg9KjExlo9LaprmvmxDMrq19J5TWkTcPSDURtUJJEM5-hDGMrOv4BfebArafJOZzu00YieUpwsUy2mGmLsVN-wfuV9xypvTQceEZy_yF-DQqt1LkIJXojLxKORe_WHs-Yzn4DU4Pfn0d-xuwVyVIPhWLmFEwH6SrsMuByM2Bg6IRTZ5b5omY_FxAoGkmURHOS7awBZN5DXkceYYrhP4G28-n2SmdUV1nqIrYk8ih1WcuxIQUtAN85ql56ABLygyAnaiqZtjjDIj4w2osJl93Aubj7SBvYgW4mRVaL5-IHl5au1sTk-k68w6bKodQKTB6TSpXnfDddWs05LORFb_-3Bla_zJQkwyN4-UsRh8EEYX8TEcCLYsLx_PO2nUZAH6Jk-emtpLXWeha5VhOJr5wu2Zus7oubwxTlNKFUeCwOEaVGg2BUSZe78ctt4xqaZ4PQA8MO0a5E6f_0m5d-TQz327mqtZbU8oSM0kjtJy-EvWXlfSh3CAB8-j6ll-aN38jk6gErPmQBEKiEzQYSQvAEZRwwEwL3XPtpvnNGTMZ17H-Oda1nPSb8Q91B6wehuERnuVIHhp3A5-HUWjtdsdg5N1VbYrM2O4JxO-3ZbnjCvRemz6Vrw==" rel="nofollow" target="_blank">LinkedIn</a>, <a href="https://www.globenewswire.com/Tracker?data=x89bAcNWaI37uteeYn1YQ1H7EKw5XrHH2KRNjweAYvBNOwiy-qt5ocv4isMkUaTxhocRZnIN_fGB-tvkeadp5kWPBLdGGnCf5sRrqx3thR4F69o26jAmtTI-Hiy4i9pvmJE7OtPgL2H5KpGrCwfEdxlVwJ0f7-f56HYSL1dHUDDYIFLOT43F-AZrMVkLx31P4OJqa8X_L_BoFYj_X7471D7FhBIXL24xcxKvEcoKIAMyrhlU8PINzrOBwx7hmndVKLCA9vBiKA2ZTB9FKt12W2R94UvJartNCvwWVNIvYSafsjVjoO1WRF7SjXNLu9dHNnWQGowwbN6GhHdJnKucojLW9-jKhVnVwydudtFyBrH-NvpSPbp-huRaZfNkp6W5B67LejZHXXp07XA84z7-WrNESku1rUHMEGTqKwKd7ZCxSgfxKTPZSbDaFXZgZXjvyDLD1SCQP66lvlMzTPvlTHeHsRV-18QZ5zwJVtxxdoAgiYs9NLK7RrN7_M_ucN92pHt2YDpm25SF51LucLlfFF3vfUJNf8Sl4h4CU2GVC4pN26ASBoj0J8ku2piuHvR5byiivAGfAd6fQeTbVWhGZ2IEj4pejEr2yzv6lszIGcRqeVJU4aDcyEq85z4vN50k7TVgF-wSN43S5mQHurCoZpV5-oHL_9_ck2U722yLhuZ7sqoLp1ceRv02kTwJm_RmexaRrylL75bt0PMFcutcszWpeP3aH6VFxEDFebPqagj-yFbujG83J3eCk1N-amC4" rel="nofollow" target="_blank">Facebook</a>, and <a href="https://www.globenewswire.com/Tracker?data=B0sKNzBjmBoMcRf6W5epYV7idP_KNLFqjaq6TtbpMxwNXYBLIDBDuZaWl2g_gRFKN17nWUxmFGMnPMsR_z9QJ9T3ucoYwuWSWaVTFke35PzZKZZwu6hgLoa79W0zCOdv3-iluPIF-lpM0Ery3juEPqrwWVEkVTf3tbteLZzM8m_R-kB_mzwrpzv8RdYKUoU2V3bop0fgttLsl82ZUsvE0KAcnrAgDFIOH0asCcGaTF3lKGArZ1C3TeN9pG_S0RiUPOCHljscOm22tx0tgT0CAqaG3RhOf2EjX_-FebvOnsiFuM64AOLTnAKofkme4jiLsrFbCsDTfqOeAOF9MnC7BXfpvE6k0L_ZpKLrKNCF-WDj8WyOevlCWc1C2gsEIKrsDVvC3_TMlRxiHI4Nle9FtFimoOHbfcJ8EA2Ch34AHqcg_t_Jf5yPdpwfpJAdOuD0cH_ty0VkOOo6tXUx6pgXRDcjT70RghGKTPu7ibTFGQw9VngkGUMOa49CWJOsSYvpXqSOoZ7-MfZGOeJ4QJ19QKcwlEE5l7PanC-XG_tjfG-oOdxr5jooLZufqVuDwsXb2i56oTF1e3cPckqBk_f1SD7Z4MU5WOCZ_ZnJT_jTxeKrFOiYdtptEePooPucG740mO0jVwwX5hOsnSp-lhxxfaLAiNT36dMx6jZq1p7Ul8pI6mIEW8wvYrHEloTeXD73BWzUd3rmNYdx00on-o1MvcfhAlNhiLKIQX5VG5fy_cata-fnasb5uUA5lrC5cNMV" rel="nofollow" target="_blank">Instagram</a>.</p>  <p><strong>Contacts:</strong>    </p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="width:49.7857%;">Media</td><td style="width:49.7857%;">Investors</td></tr><tr><td style="width:49.7857%;">Christian Glazar</td><td style="width:49.7857%;">Pravesh Khandelwal</td></tr><tr><td style="width:49.7857%;">Sr. Director, Corporate Communications</td><td style="width:49.7857%;">VP, Head of Investor Relations</td></tr><tr><td style="width:49.7857%;">908-821-6922</td><td style="width:49.7857%;">551-264-6547</td></tr><tr><td style="width:49.7857%;"><a href="mailto:media.relations@embecta.com" rel="nofollow" target="_blank">Contact Media Relations</a></td><td style="width:49.7857%;"><a href="mailto:investor.relations@embecta.com" rel="nofollow" target="_blank">Contact IR</a></td></tr></table> <p><br></br></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTgwNTUxMSM3NzY0MDMwIzIyNDQ1Njk="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/MTA2OWRiZWYtMGIwZC00N2FiLTg1MWYtOWUwZWIxM2VjNmQ5LTEyNTYxMjItMjAyNi0wOC0wNy1lbg==/tiny/Embecta-Corp-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/fa3e492e-f542-4291-a7e2-bdd2c3dff424"><img src="https://ml.globenewswire.com/media/fa3e492e-f542-4291-a7e2-bdd2c3dff424/small/embecta-logo-jpg.jpg" border="0" width="150" height="75" alt="Primary Logo"></img></a></p>

Embecta disclosed its third-quarter fiscal 2026 results and will host a live 8:00 a.m. ET conference call and webcast for analysts and investors. The company reiterates its strategy to evolve from insulin delivery to a broad-based medical supplies player with about 2,000 employees globally. A detailed earnings press release and investor presentation are available on its IR site.

News insight

Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results

AI summary

Sentiment rationale

Key facts

Earnings